Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Li, Jonathan Z ^a,b   Brumme, Chanson J ^c   Lederman, Michael M ^d   Brumme, Zabrina L ^c,e   Wang, Hongying ^f   Spritzler, John ^f   Carrington, Mary ^c,g   Medvik, Kathleen ^d   Walker, Bruce D ^b,c,h   Schooley, Robert T ⁱ   Kuritzkes, Daniel R ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD UNIVERSITY   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e SIMON FRASER UNIVERSITY   (Canada)

^f CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^g SAIC FREDERICK INC   (United States)

^h HOWARD HUGHES MEDICAL INSTITUTE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAG PROTEIN; GAMMA INTERFERON; HIV 1 GAG VACCINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; POL PROTEIN; PROGRAMMED DEATH 1 RECEPTOR; RECOMBINANT ADENOVIRUS 5 VECTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS RNA; CYTOKINE; PDCD1 PROTEIN, HUMAN; RECOMBINANT VACCINE;

ADULT; AMINO ACID SEQUENCE; ANALYTIC TREATMENT INTERRUPTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RESPONSE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE AMPLIFICATION; HEALTH CARE CONCEPTS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; INTERFERON PRODUCTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; TREATMENT OUTCOME; UNINDEXED SEQUENCE; VACCINATION; VIRUS INHIBITION; VIRUS LOAD; BIOSYNTHESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOLOGY; DNA SEQUENCE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE SYSTEM; METHODOLOGY; MIDDLE AGED; MOLECULAR GENETICS; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; AIDS VACCINES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CTLA-4 ANTIGEN; CYTOKINES; FEMALE; FLOW CYTOMETRY; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; HUMANS; IMMUNE SYSTEM; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PLACEBOS; PROGRAMMED CELL DEATH 1 RECEPTOR; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; VACCINES, SYNTHETIC;

EID: 84859141780     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034134     Document Type: Article

References (34)

1. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, et al. (2009) The challenge of finding a cure for HIV infection. Science 323: 1304-1307.
2. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304: 321-333.
3. Johnston R, (2010) HIV cure: controversy, consensus, and a consortium. AIDS Res Hum Retroviruses 26: 943-946.
4. Folkers GK, Fauci AS, (2010) Controlling and ultimately ending the HIV/AIDS pandemic: a feasible goal. JAMA 304: 350-351.
5. Lederman MM, Penn-Nicholson A, Stone SF, Sieg SF, Rodriguez B, (2007) Monitoring clinical trials of therapeutic vaccines in HIV infection: role of treatment interruption. Curr Opin HIV AIDS 2: 56-61.
6. Schooley RT, Spritzler J, Wang H, Lederman MM, Havlir D, et al. (2010) AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis 202: 705-716.
7. Li JZ, Brumme ZL, Brumme CJ, Wang H, Spritzler J, et al. (2011) Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. J Infect Dis 203: 976-983.
8. van den Berg-Wolf M, Hullsiek KH, Peng G, Kozal MJ, Novak RM, et al. (2008) Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. HIV Clin Trials 9: 324-336.
9. Murphy RA, Sunpath H, Lu Z, Chelin N, Losina E, et al. (2010) Outcomes after virologic failure of first-line ART in South Africa. AIDS 24: 1007-1012.
10. Babiker A, Castro nee Green H, Compagnucci A, Fiscus S, Giaquinto C, et al. (2011) First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis 11: 273-283.
11. Miller LG, Golin CE, Liu H, Hays RD, Hua J, et al. (2004) No evidence of an association between transient HIV viremia ("Blips") and lower adherence to the antiretroviral medication regimen. J Infect Dis 189: 1487-1496.
12. Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, et al. (2005) Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis 41: 1326-1332.
13. Gao X, Nelson GW, Karacki P, Martin MP, Phair J, et al. (2001) Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med 344: 1668-1675.
14. Tobery TW, Dubey SA, Anderson K, Freed DC, Cox KS, et al. (2006) A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjects. AIDS Res Hum Retroviruses 22: 1081-1090.
15. Trigona WL, Clair JH, Persaud N, Punt K, Bachinsky M, et al. (2003) Intracellular staining for HIV-specific IFN-gamma production: statistical analyses establish reproducibility and criteria for distinguishing positive responses. J Interferon Cytokine Res 23: 369-377.
16. Brumme ZL, John M, Carlson JM, Brumme CJ, Chan D, et al. (2009) HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS ONE 4: e6687.
17. Le Moing V, Chene G, Carrieri MP, Alioum A, Brun-Vezinet F, et al. (2002) Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 16: 21-29.
18. Ioannidis JP, Havlir DV, Tebas P, Hirsch MS, Collier AC, et al. (2000) Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication. AIDS 14: 1481-1488.
19. Fagard C, Oxenius A, Gunthard H, Garcia F, Le Braz M, et al. (2003) A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med 163: 1220-1226.
20. Altfeld M, Addo MM, Rosenberg ES, Hecht FM, Lee PK, et al. (2003) Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. Aids 17: 2581-2591.
21. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, et al. (2004) Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432: 769-775.
22. Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, et al. (2006) HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med 3: e403.
23. Honeyborne I, Prendergast A, Pereyra F, Leslie A, Crawford H, et al. (2007) Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes. J Virol 81: 3667-3672.
24. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, et al. (2010) The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330: 1551-1557.
25. Fitzgerald DW, Janes H, Robertson M, Coombs R, Frank I, et al. (2011) An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study). J Infect Dis 203: 765-772.
26. Boritz E, Palmer BE, Wilson CC, (2004) Human immunodeficiency virus type 1 (HIV-1)-specific CD4+ T cells that proliferate in vitro detected in samples from most viremic subjects and inversely associated with plasma HIV-1 levels. J Virol 78: 12638-12646.
27. Ramduth D, Day CL, Thobakgale CF, Mkhwanazi NP, de Pierres C, et al. (2009) Immunodominant HIV-1 Cd4+ T cell epitopes in chronic untreated clade C HIV-1 infection. PLoS One 4: e5013.
28. Prendergast A, Goodliffe H, Clapson M, Cross R, Tudor-Williams G, et al. (2011) Gag-specific CD4+ T-cell responses are associated with virological control of paediatric HIV-1 infection. AIDS.
29. Autran B, Murphy RL, Costagliola D, Tubiana R, Clotet B, et al. (2008) Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS 22: 1313-1322.
30. Papagno L, Alter G, Assoumou L, Murphy RL, Garcia F, et al. (2011) Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. AIDS 25: 27-36.
31. Kaufmann DE, Walker BD, (2009) PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol 182: 5891-5897.
32. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, et al. (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354.
33. Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, et al. (2007) Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 8: 1246-1254.
34. Riley JL, Schlienger K, Blair PJ, Carreno B, Craighead N, et al. (2000) Modulation of susceptibility to HIV-1 infection by the cytotoxic T lymphocyte antigen 4 costimulatory molecule. J Exp Med 191: 1987-1997.